[Lipid peroxidation and antioxidative protection in patients with coronary heart disease].

Total cholesterol as well as cholesterol of low and high density lipoproteins, lipid peroxidation products (LPP), such as dienic conjugates and compounds reacting with thiobarbituric acid, were measured in a single blood sample from each of the 295 patients with CHD and 20 apparently healthy subjects. FC II and III angina was diagnosed in 142 and 151 CHD patients respectively. Certain samples were used to additionally detect homocysteine, activity of anti-oxidative enzymes (superoxide dismutase and glutathione peroxidase) in erythrocytes and ceruloplasmin/transferrin anti-oxidative system in plasma. Patients with FC III angina had significantly higher LPP levels but lower activity of tissue and plasma anti-oxidative systems than patients with FC II angina or healthy subjects. Patients with stable forms of CHD showed correlation between lipid composition, LPP contents, homocysteine level, and activity of anti-oxidative enzymes.

[Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia].

The subjects of the study were 43 patients with II- III functional class coronary heart disease (CHD) and dyslipidemia, who received conventional cardial therapy. The patients were divided into two groups: group I (26 subjects) received vasilip, a simvastatin generic, in a dose of 20 mg a day; group 11 (17 subjects) received vasilip in a dose of 20 mg a day plus cudesan in a dose of 1 ml a day, which contained 30 mg of ubiquinone Q 10 and 4.5 mg of alpha-tocopherol. Effects of the therapies on blood lipids, their peroxides, and the antioxidative status of blood were studied. After one month, vasilip was effective in achieving the target level of low-density lipoprotein cholesterol in 62% of group I patients and 65% of group II patients; at the same time, its use led to a significant increase in the level of primary and secondary lipid peroxidation (LP) products (25% and 29%, respectively), and lowering of the antioxidative status of blood, which consisted in a decrease in ceruloplasmin (CP) serum level and CP: transferrin (CP:TF) ratio by 6% in group I patients. The use of cudesan in combination with vasilip led to a significant decrease in the level of primary and secondary LP products (30% and 29%, respectively), and an increase in the level of serum CP by 25.7%, and CP: TF ratio by 12.5%.

[Disorders of fatty acid composition and the processes of lipid peroxidation in chronic ischemic heart disease]. / Narusheniia sostava zhirnykh kislot i protsessov perekisnogo okisleniia lipidov pri khronicheskoi ishemicheskoi bolezni serdtsa.

The levels of lipid fractions, free and bound fatty acids, initial and end lipid peroxidation products in the blood plasma, red cell membrane resistance to hemolysis, and myocardial contractility before, during, and after therapy with lipostabil forte (0.6-1.8 g daily or 10 ml (0.5 g) i.v.) and bezafibrate (0.2 g 3 times daily) along with nitrates (10 to 30 tablets) have been examined by the routine methods in 159 patients with stable angina pectoris and postinfarction cardiosclerosis. A negative effect of high doses of nitrates on myocardial hemodynamics and fatty acid composition has been revealed, resulting in accumulation of bound fatty acids. Lipostabil has improved the patients' status, myocardial function, and lipid composition, reduced the levels of atherogenic lipids and lipid peroxidation products, as well as the concentration of fatty acids with an uneven number of C atoms, increased the fatty acid nonsaturation index and the level of medium-strand fatty acids. Improvement of the patient's condition in bezafibrate therapy has been less evident; the concentration of atherogenic lipids has been reduced, but the levels of bound fatty acids and of lipid peroxidation products has increased. Bezafibrate is recommended to be administered together with antioxidants.

[Diagnostic value of studying the indicators of blood lipid composition and the status of intravascular microcirculation in patients with diabetes mellitus associated with ischemic heart disease]. / Diagnosticheskaia zhachimost' issledovaniia pokazatelei lipidnogo sostava krovi i sostoianiia vnutrisosudistoi mikrotsirkuliastii u bol'nykh sakharnym diabetom v sochetanii s ischemicheskoi bolezn'iu serdtsa.

A comprehensive study of blood lipid composition and microcirculatory indices was performed in 88 patients with diabetes mellitus (DM) combined with coronary heart disease (CHD). A "syndrome" of mutual aggravation was shown to develop in the combination of DM and CHD. As a result of it the above indices were changed depending on clinical signs of each of the two diseases. Lipid metabolic and microcirculatory derangements depended mostly on a degree of compensation of carbohydrate metabolism. a DM type, the presence of diabetic angiopathies and CHD gravity.